Fig. 1

Inhibition of proliferation of Imatinib-sensitive and –resistant CML cell lines. Imatinib-sensitive K562 (a), KCL22 (c), and BaF3 Bcr-Abl WT (e) and Imatinib-resistant K562-R (b), KCL22-R (d), and BaF3 Bcr-Abl T315I (f) CML cell lines were CFSE-labelled and treated with increasing concentrations of drugs for five days before analysis of cell fluorescence in a flow cytometer. Negative and positive controls of proliferation were obtained with actinomycin D-treated or untreated cells, respectively. Each experiment was done twice